These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 28911074)

  • 1. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
    Lim SH; Hong JY; Lim ST; Hong H; Arnoud J; Zhao W; Yoon DH; Tang T; Cho J; Park S; Ko YH; Kim SJ; Suh C; Lin T; Kim WS
    Ann Oncol; 2017 Sep; 28(9):2199-2205. PubMed ID: 28911074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
    Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
    Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A five
    Vittayawacharin P; Khuhapinant A
    Hematology; 2021 Dec; 26(1):75-82. PubMed ID: 33427594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
    Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
    Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and Prognosis of Newly Diagnosed Advanced-Stage Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Real-World Study across Two Decades.
    Wei YC; Qi F; Chen B; Zhang CG; Fang H; Zhang D; Qi SN; Chai Y; Li YX; Dong M
    Chemotherapy; 2024; 69(2):108-121. PubMed ID: 37984344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
    Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
    Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
    Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
    Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
    Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
    Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
    Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
    EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose extended-field radiotherapy plus chemotherapy improved survival in extranodal NK/T-cell lymphoma in a real-life setting: results from the multicenter T-Cell Brazil Project.
    de Pádua Covas Lage LA; Machado PPF; Reichert CO; Miranda E; Culler HF; da Siqueira SAC; de Oliveira Costa R; Miyashiro DR; Sanches JA; Rocha V; Chiattone CS; Pereira J
    Sci Rep; 2022 Nov; 12(1):20557. PubMed ID: 36446856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
    Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.
    Tian J; Hao M; Liu Q; Xiao F; Li Y; Qi M; Gao J; Liu L; Yin D
    Hematol Oncol; 2023 Aug; 41(3):396-406. PubMed ID: 36516297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphoma.
    Nie M; Bi XW; Zhang WW; Sun P; Xia Y; Liu PP; Huang HQ; Jiang WQ; Li ZM
    Sci Rep; 2016 Apr; 6():23996. PubMed ID: 27041507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage treatment improved survival of patients with relapsed extranodal natural killer/t-cell lymphoma, nasal type.
    Zhang XX; Xie CH; Xu Y; Deng D; Zhao YH; Zou BW; Zhou L; Li M; Wang J; Liu WP; Huang MJ
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):747-52. PubMed ID: 19304409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
    Jaccard A; Gachard N; Marin B; Rogez S; Audrain M; Suarez F; Tilly H; Morschhauser F; Thieblemont C; Ysebaert L; Devidas A; Petit B; de Leval L; Gaulard P; Feuillard J; Bordessoule D; Hermine O;
    Blood; 2011 Feb; 117(6):1834-9. PubMed ID: 21123825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive therapy can improve long-term survival in newly diagnosed, advanced-stage extranodal NK/T-cell lymphoma: A multi-institutional, real-world study.
    Wei YC; Qi F; Zheng BM; Zhang CG; Xie Y; Chen B; Liu WX; Liu WP; Fang H; Qi SN; Zhang D; Chai Y; Li YX; Wang WH; Song YQ; Zhu J; Dong M
    Int J Cancer; 2023 Nov; 153(9):1643-1657. PubMed ID: 37539660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
    Zhang Y; Ma S; Cai J; Yang Y; Jing H; Shuang Y; Peng Z; Li B; Liu P; Xia Z; Xia Y; Gao Y; Chen D; Lin J; Li Q; Xu S; Xu Q; Zhang H; Huang H; Cai Q
    Am J Hematol; 2021 Nov; 96(11):1481-1490. PubMed ID: 34449095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma.
    Wu W; Ren K; Chen X; Li N; Luo Q; Hai T; Zhou H; Zou L
    Cancer Med; 2023 Apr; 12(8):9458-9470. PubMed ID: 37000008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up.
    Wang L; Wang WD; Xia ZJ; Zhang YJ; Xiang J; Lu Y
    Med Oncol; 2014 Mar; 31(3):860. PubMed ID: 24481637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study.
    Xu Y; Wang J; Zhang W; Liu J; Cao X; He A; Chen Y; Gu L; Lei B; Zhang P; Ma X
    Med Sci Monit; 2016 Nov; 22():4297-4311. PubMed ID: 27843135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.